Clinical Trials Logo

Clinical Trial Summary

This study is designed to determine the safety and immunogenicity of an inactivated Rift Valley Fever (RVF) Vaccine in adults


Clinical Trial Description

The primary objectives are to assess safety of Rift Valley Fever (RVF) Vaccine, Inactivated (TSI-GSD 200) and to assess immunogenicity of Rift Valley Fever (RVF) Vaccine, Inactivated (TSI-GSD 200). The secondary objective is to assess incidence of RVF infection in vaccinated personnel ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00869713
Study type Interventional
Source U.S. Army Medical Research and Development Command
Contact
Status Completed
Phase Phase 2
Start date September 2009
Completion date May 2021

See also
  Status Clinical Trial Phase
Recruiting NCT05139524 - RVF and Other Emerging Infectious Diseases in East and Central Africa
Recruiting NCT03609398 - Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine Phase 2
Completed NCT04672824 - A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy Adults Phase 1
Completed NCT00287014 - Rift Valley Fever in Kenya N/A
Completed NCT00584194 - Safety and Immunogenicity Study of Rift Valley Fever Vaccine Phase 2
Completed NCT04754776 - Safety and Immunogenicity of a Candidate RVFV Vaccine (RVF001) Early Phase 1
Completed NCT00415051 - Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine Phase 2